Fig. 3
NUAK2-dependency in YAP-driven cancer lines. a Growth curves of HuCCT-1 and SNU475 cells transfected with either scrambled (ctrl) or NUAK2 sgRNAs using crystal violet assessment of cell growth. Data are presented as mean ± SD; n = 6. b Growth curves of HuCCT-1 cells transfected with scramble or NUAK2 sgRNA and/or vectors expressing cDNAs encoding wild-type or kinase-dead NUAK2 with a mutated PAM sequence, thus the construct DNA would not be targeted by Cas9. Data are presented as mean ± SD; n = 5. The expression of NUAK2 is shown in Supplementary Fig. 3c. c Western blot and qPCR analysis depicting levels of phospho-S445 MYPT1, MYPT1, YAP, TAZ, and NUAK2 in various human liver cancer cell lines. d Cell growth curves of liver cancer cell lines following transfection with siRNAs against YAP/TAZ, NUAK2 or control sequence. Data are presented as mean ± SD; n = 4. The knockdown efficiency of YAP, TAZ, and NUAK2 is shown in Supplementary Fig. 3f–h. e Western blot analysis depicting levels of NF2, YAP, and phospho-S127 YAP in indicated human cancer cell lines. f Cell growth curves of indicated cancer cell lines following transfection with siRNAs against NUAK2 or control sequence. Data are presented as mean ± SD; n = 6. The knockdown efficiency of NUAK2 is shown in Supplementary Fig. 3i
